Ketogenic Diet in Oncology

Metabolic therapy targeting the Warburg effect — heavily queried, controversial, and evidence-limited

Key Points

• The ketogenic diet (very-low-carbohydrate, high-fat) is proposed to exploit the Warburg effect — many tumors rely on glucose/glycolysis and cannot efficiently use ketone bodies for fuel.
• Human evidence is limited to small feasibility and Phase I/II trials; there is no Phase III survival data supporting KD as an anticancer treatment.
• Best-studied setting is glioblastoma, where small trials show feasibility and possible synergy with standard chemoradiation, but results are preliminary.
• KD reliably lowers insulin and IGF-1 signaling, which is mechanistically relevant to insulin-responsive tumors — but this does not equal proven clinical benefit.
• Not appropriate for all patients: risk of unintended weight loss and muscle wasting in cachexia-prone cancers makes it potentially harmful without supervision.
• Should be undertaken only with oncology and dietitian oversight; it is a research and supportive intervention, not a substitute for standard therapy.

Rationale: The Warburg Effect

The ketogenic diet's oncological rationale rests on the **Warburg effect** — the observation that many cancer cells preferentially metabolize glucose via aerobic glycolysis (fermentation to lactate) even when oxygen is available, rather than oxidative phosphorylation. This is exploited clinically every day: FDG-PET imaging visualizes tumors precisely because of their high glucose avidity. The hypothesis is that a very-low-carbohydrate, high-fat diet lowers blood glucose and insulin while raising ketone bodies (β-hydroxybutyrate, acetoacetate). Because many tumor cells have dysfunctional…

Clinical Evidence

The clinical evidence remains **preliminary and should be communicated honestly** to patients who ask. **Glioblastoma:** This is the most active research area, partly because the brain adapts well to ketones. Small feasibility trials (e.g., ERGO, ERGO2) show KD is tolerable in GBM patients and can be combined with standard temozolomide chemoradiation. The ERGO2 randomized trial (Rieger et al.) combined a ketogenic diet with intermittent fasting during reirradiation and found it feasible and safe but did not demonstrate a progression-free survival benefit. Ongoing trials continue to evaluate…

Patient Selection and Risks

The most important clinical judgment is **who should not attempt this**. Because many cancers and cancer treatments drive weight loss and cachexia, imposing a restrictive, often calorie-reducing diet can be actively harmful. KD is generally inappropriate for: - Patients with, or at high risk of, cancer cachexia or sarcopenia - Patients with poor performance status or ongoing unintended weight loss - Patients on insulin or sulfonylureas without close glucose monitoring, and those on SGLT2 inhibitors (euglycemic DKA risk) - Patients with pancreatitis, significant hepatic disease, or fatty-acid…

Clinical Applications and Counseling

**Framing for patients:** Ketogenic diets are among the most-searched topics in integrative oncology, often driven by online claims of "starving cancer." Clinicians should neither dismiss nor overpromise: acknowledge the sound underlying biology (Warburg effect, insulin/IGF-1 reduction) while being clear that human proof of anticancer benefit does not yet exist and that the diet carries real risks. **If pursued:** It should be done under combined oncology and registered-dietitian supervision, with attention to maintaining protein and total calorie adequacy to protect lean mass, monitoring of…